Feng and Navaratna demonstrated that the initial ratio between regulatory T cells and effector T cells impacts the tumour recurrence time and that the effectiveness of IL-2 use may reverse the immunotherapy outcome [15]. The gene discussed is IL2; the disease is neoplasm.